Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Neisseria gonorrhoeae as a Rare Cause of Preseptal Cellulitis.

Adamson PC, Judson SD, Klausner JD, Kelesidis T.

Sex Transm Dis. 2019 Jul 25. doi: 10.1097/OLQ.0000000000001055. [Epub ahead of print]

PMID:
31356532
2.

The impact of aerobic and isometric exercise on different measures of dysfunctional high-density lipoprotein in patients with hypertension.

Pagonas N, Vlatsas S, Bauer F, Seibert FS, Sasko B, Buschmann I, Ritter O, Kelesidis T, Westhoff TH.

Eur J Prev Cardiol. 2019 Aug;26(12):1301-1309. doi: 10.1177/2047487319848199. Epub 2019 May 8.

3.

High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort.

Samadi S, Mehramiz M, Kelesidis T, Mobarhan MG, Sahebkar AH, Esmaily H, Moohebati M, Farjami Z, Ferns GA, Mohammadpour AH, Avan A.

J Cell Physiol. 2019 Feb 19. doi: 10.1002/jcp.28276. [Epub ahead of print]

PMID:
30784041
4.

Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.

Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, Perakakis N, Koniaris A, Kelesidis T, Mantzoros CS.

Diabetes Obes Metab. 2019 Jun;21(6):1487-1492. doi: 10.1111/dom.13655. Epub 2019 Mar 18.

PMID:
30724455
5.

Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.

Samadi S, Abolbashari S, Meshkat Z, Mohammadpour AH, Kelesidis T, Gholoobi A, Mehramiz M, Tabadkani M, Sadabadi F, Dalirfardouei R, Ferns GA, Ghayour-Mobarhan M, Avan A.

Biofactors. 2019 May;45(3):374-380. doi: 10.1002/biof.1489. Epub 2019 Jan 29.

6.

The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation.

Christodoulides A, Gupta N, Yacoubian V, Maithel N, Parker J, Kelesidis T.

Front Microbiol. 2018 Jul 31;9:1682. doi: 10.3389/fmicb.2018.01682. eCollection 2018.

7.

Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332.

Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AM.

Medicine (Baltimore). 2018 Jun;97(22):e10955. doi: 10.1097/MD.0000000000010955.

8.

Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s.

Kelesidis T, Moser CB, Johnston E, Stein JH, Dube MP, Yang OO, McComsey GA, Currier JS, Brown TT.

J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):362-366. doi: 10.1097/QAI.0000000000001679.

9.

Low Levels of Endothelial Progenitor Cells and Their Association with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men.

Seang S, Kelesidis T, Huynh D, Park S, Moe AA, Currier JS, Lake JE.

AIDS Res Hum Retroviruses. 2018 Jan;34(1):39-45. doi: 10.1089/AID.2017.0057.

10.

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions.

Angelovich TA, Hearps AC, Maisa A, Kelesidis T, Jaworowski A.

J Vis Exp. 2017 Oct 17;(128). doi: 10.3791/56293.

11.

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein.

Sen Roy S, Nguyen HCX, Angelovich TA, Hearps AC, Huynh D, Jaworowski A, Kelesidis T.

J Vis Exp. 2017 Oct 12;(128). doi: 10.3791/56325.

12.

Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro.

Angelovich TA, Hearps AC, Oda MN, Borja MS, Huynh D, Homann S, Jaworowski A, Kelesidis T.

AIDS. 2017 Nov 13;31(17):2331-2336. doi: 10.1097/QAD.0000000000001642.

13.

A novel rapid and reproducible flow cytometric method for optimization of transfection efficiency in cells.

Homann S, Hofmann C, Gorin AM, Nguyen HCX, Huynh D, Hamid P, Maithel N, Yacoubian V, Mu W, Kossyvakis A, Sen Roy S, Yang OO, Kelesidis T.

PLoS One. 2017 Sep 1;12(9):e0182941. doi: 10.1371/journal.pone.0182941. eCollection 2017.

14.

Spirochetal Lipoproteins and Immune Evasion.

Christodoulides A, Boyadjian A, Kelesidis T.

Front Immunol. 2017 Mar 29;8:364. doi: 10.3389/fimmu.2017.00364. eCollection 2017. Review.

15.

Detection of Donor-Derived Microparticles in the Peripheral Blood of a Hand Transplant Recipient During Rejection.

Kim JY, Kelesidis T, Yang OO.

Transplant Direct. 2017 Feb 7;3(3):e131. doi: 10.1097/TXD.0000000000000646. eCollection 2017 Mar.

16.

Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals.

Kelesidis T, Oda MN, Borja MS, Yee Y, Ng KF, Huynh D, Elashoff D, Currier JS.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):354-363. doi: 10.1097/QAI.0000000000001383.

17.

Rhodococcus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients1.

Vergidis P, Ariza-Heredia EJ, Nellore A, Kotton CN, Kaul DR, Morris MI, Kelesidis T, Shah H, Park SY, Nguyen MH, Razonable RR.

Emerg Infect Dis. 2017 Mar;23(3):510-512. doi: 10.3201/eid2303.160633.

18.

γH2Ax Expression as a Potential Biomarker Differentiating between Low and High Grade Cervical Squamous Intraepithelial Lesions (SIL) and High Risk HPV Related SIL.

Leventakos K, Tsiodras S, Kelesidis T, Kefala M, Kottaridi C, Spathis A, Gouloumi AR, Pouliakis A, Pappas A, Sioulas V, Chrelias C, Karakitsos P, Panayiotides I.

PLoS One. 2017 Jan 24;12(1):e0170626. doi: 10.1371/journal.pone.0170626. eCollection 2017.

19.

Assessment of Telomere Length, Phenotype, and DNA Content.

Kelesidis T, Schmid I.

Curr Protoc Cytom. 2017 Jan 5;79:7.26.1-7.26.23. doi: 10.1002/cpcy.12.

20.

Weight loss surgery in adolescents corrects high-density lipoprotein subspecies and their function.

Davidson WS, Inge TH, Sexmith H, Heink A, Elder D, Hui DY, Melchior JT, Kelesidis T, Shah AS.

Int J Obes (Lond). 2017 Jan;41(1):83-89. doi: 10.1038/ijo.2016.190. Epub 2016 Oct 26.

21.

Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.

Kelesidis T, Jackson N, McComsey GA, Wang X, Elashoff D, Dube MP, Brown TT, Yang OO, Stein JH, Currier JS.

AIDS. 2016 Nov 13;30(17):2625-2633.

22.

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.

Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, Currier J, McComsey GA.

Open Forum Infect Dis. 2016 Aug 29;3(3):ofw174. eCollection 2016 Sep.

23.

Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.

Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS.

Antivir Ther. 2017;22(2):113-126. doi: 10.3851/IMP3093. Epub 2016 Sep 23.

24.

Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

Lake JE, Seang S, Kelesidis T, Currier JS, Yang OO.

HIV Clin Trials. 2016 Nov;17(6):225-232. Epub 2016 Sep 23.

25.

Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube MP, Yang OO, Currier JS, McComsey GA.

J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. Epub 2016 Jun 28.

26.

Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332.

Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AM, Aberg JA.

Inflammation. 2016 Aug;39(4):1354-62. doi: 10.1007/s10753-016-0367-6.

27.

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT.

Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017. Epub 2016 Jan 20.

28.

First Report of Ventriculoperitoneal Shunt Infection due to Cyberlindnera fabianii.

Baghdadi J, Hemarajata P, Humphries R, Kelesidis T.

Case Rep Infect Dis. 2015;2015:630816. doi: 10.1155/2015/630816. Epub 2015 Nov 4.

29.

The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.

Kelesidis T, Papakonstantinou V, Detopoulou P, Fragopoulou E, Chini M, Lazanas MC, Antonopoulou S.

AIDS Rev. 2015 Oct-Dec;17(4):191-201. Review.

30.

Indications and Types of Antibiotic Agents Used in 6 Acute Care Hospitals, 2009-2010: A Pragmatic Retrospective Observational Study.

Kelesidis T, Braykov N, Uslan DZ, Morgan DJ, Gandra S, Johannsson B, Schweizer ML, Weisenberg SA, Young H, Cantey J, Perencevich E, Septimus E, Srinivasan A, Laxminarayan R.

Infect Control Hosp Epidemiol. 2016 Jan;37(1):70-9. doi: 10.1017/ice.2015.226. Epub 2015 Oct 12.

PMID:
26456803
31.

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.

Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube MP, Murphy RL, Currier JS.

AIDS. 2015 Sep 10;29(14):1775-83. doi: 10.1097/QAD.0000000000000762. Erratum in: AIDS. 2016 Jan;30(2):337.

32.

The safety of polymyxin antibiotics.

Kelesidis T, Falagas ME.

Expert Opin Drug Saf. 2015;14(11):1687-701. doi: 10.1517/14740338.2015.1088520. Epub 2015 Sep 12. Review.

PMID:
26365594
33.

Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.

Lake JE, Seang S, Kelesidis T, Liao DH, Hodis HN, Stein JH, Currier JS.

HIV Clin Trials. 2015 Oct;16(5):197-206. doi: 10.1179/1945577115Y.0000000006. Epub 2015 Sep 11.

34.

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.

Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14. Epub 2015 May 11.

35.

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA.

J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5.

36.

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA.

Clin Infect Dis. 2015 Aug 15;61(4):651-60. doi: 10.1093/cid/civ327. Epub 2015 Apr 22.

37.

Substandard/counterfeit antimicrobial drugs.

Kelesidis T, Falagas ME.

Clin Microbiol Rev. 2015 Apr;28(2):443-64. doi: 10.1128/CMR.00072-14. Review.

38.

Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study.

Braykov NP, Morgan DJ, Schweizer ML, Uslan DZ, Kelesidis T, Weisenberg SA, Johannsson B, Young H, Cantey J, Srinivasan A, Perencevich E, Septimus E, Laxminarayan R.

Lancet Infect Dis. 2014 Dec;14(12):1220-7. doi: 10.1016/S1473-3099(14)70952-1. Epub 2014 Nov 17.

39.

How to approach and treat viral infections in ICU patients.

Kelesidis T, Mastoris I, Metsini A, Tsiodras S.

BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/1471-2334-14-321. Review.

40.

A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL.

Kelesidis T, Roberts CK, Huynh D, Martínez-Maza O, Currier JS, Reddy ST, Yang OO.

PLoS One. 2014 Nov 4;9(11):e111716. doi: 10.1371/journal.pone.0111716. eCollection 2014.

41.

Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.

Kelesidis T, Currier JS.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):665-84. doi: 10.1016/j.ecl.2014.06.003. Review.

42.

Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial.

Yang OO, Kelesidis T, Cordova R, Khanlou H.

AIDS Res Hum Retroviruses. 2014 Oct;30(10):988-95. doi: 10.1089/AID.2014.0181. Epub 2014 Sep 11.

43.

Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Kelesidis T, Currier JS, Yang OO, Brown TT.

AIDS Rev. 2014 Jul-Sep;16(3):123-33. Review.

44.

The Cross-Talk between Spirochetal Lipoproteins and Immunity.

Kelesidis T.

Front Immunol. 2014 Jun 30;5:310. doi: 10.3389/fimmu.2014.00310. eCollection 2014. Review.

45.

Mechanisms of linezolid resistance among coagulase-negative staphylococci determined by whole-genome sequencing.

Tewhey R, Gu B, Kelesidis T, Charlton C, Bobenchik A, Hindler J, Schork NJ, Humphries RM.

MBio. 2014 May 13;5(3):e00894-14. doi: 10.1128/mBio.00894-14.

46.

The Interplay between Daptomycin and the Immune System.

Kelesidis T.

Front Immunol. 2014 Feb 12;5:52. doi: 10.3389/fimmu.2014.00052. eCollection 2014. Review.

47.

HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.

Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, Wai B, Marmarelis E, Hernandez NJ, Yang OO, Currier JS, Grinspoon SK.

Antivir Ther. 2014;19(8):805-811. doi: 10.3851/IMP2756. Epub 2014 Feb 17.

48.

The zoonotic potential of daptomycin non-susceptible enterococci.

Kelesidis T.

Zoonoses Public Health. 2015 Feb;62(1):1-6. doi: 10.1111/zph.12091. Epub 2013 Nov 26. Review.

49.

Frequency of susceptibility testing for patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Giltner CL, Kelesidis T, Hindler JA, Bobenchik AM, Humphries RM.

J Clin Microbiol. 2014 Jan;52(1):357-61. doi: 10.1128/JCM.02081-13. Epub 2013 Oct 23.

50.

Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status.

Roberts CK, Katiraie M, Croymans DM, Yang OO, Kelesidis T.

J Appl Physiol (1985). 2013 Oct 1;115(7):1043-9. doi: 10.1152/japplphysiol.00359.2013. Epub 2013 Jul 25.

Supplemental Content

Loading ...
Support Center